Dr. Shuhua Xia has over 20 years of experience in the biotech industry, with expertise in the development of antibody-based therapeutics.Prior to joining DiligeneBio, Dr. Xia spent more than 15 years at Pfizer’s R&D division, where he worked across multiple biotherapeutic areas—including antibodies and antibody-drug conjugates (ADCs). Notably, he contributed to the development of the ADC drug inotuzumab ozogamicin, which was successfully launched. Dr. Xia holds a Ph.D. in Genetics from Peking Union Medical College and a MS degree in Biostatistics from Texas A&M University. He finished his postdoc. training at Harvard Medical School.